Y Intercept Hong Kong Ltd Buys Shares of 14,285 AxoGen, Inc. (NASDAQ:AXGN)

Y Intercept Hong Kong Ltd bought a new stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,285 shares of the medical equipment provider's stock, valued at approximately $235,000.

A number of other large investors have also modified their holdings of AXGN. Creative Planning raised its stake in shares of AxoGen by 152.2% in the third quarter. Creative Planning now owns 29,790 shares of the medical equipment provider's stock valued at $418,000 after purchasing an additional 17,980 shares in the last quarter. Sentry Investment Management LLC grew its position in AxoGen by 9.3% in the third quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider's stock valued at $243,000 after acquiring an additional 1,483 shares during the period. Principal Financial Group Inc. bought a new stake in AxoGen in the third quarter valued at $207,000. Primoris Wealth Advisors LLC bought a new stake in AxoGen in the third quarter valued at $207,000. Finally, Los Angeles Capital Management LLC bought a new stake in AxoGen in the third quarter valued at $279,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Price Performance

Shares of AXGN stock traded down $0.04 during trading hours on Friday, hitting $17.73. 636,905 shares of the company's stock were exchanged, compared to its average volume of 557,396. The stock's 50-day moving average is $17.90 and its 200-day moving average is $15.26. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The stock has a market cap of $786.22 million, a price-to-earnings ratio of -55.41 and a beta of 1.00. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $21.00.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AXGN shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $24.00 price target on shares of AxoGen in a research report on Wednesday. Canaccord Genuity Group upped their price target on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, February 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $20.75.

Insider Transactions at AxoGen

In other news, Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the sale, the director now owns 97,899 shares in the company, valued at approximately $1,959,937.98. This represents a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.00% of the company's stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.